View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 5, 2019updated 07 Aug 2019 2:57pm

Eli Lilly reports positive data from atopic dermatitis trials

A partnership between Eli Lilly and Company and Incyte has reported positive top-line results from the Phase III BREEZE-AD1 and BREEZE-AD2 trials after the studies met their primary endpoints.

Eli Lilly and Company and its study partner Incyte has reported positive top-line results from the Phase III BREEZE-AD1 and BREEZE-AD2 trials after the studies met their primary endpoints.

Both trials are investigating the efficacy and safety of baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).

AD is a chronic, relapsing skin disease that causes intense itching, dry skin, and inflammation on any part of the body.

The latest data shows that a statistically important proportion of patients receiving baricitinib achieved the primary endpoint at week 16 as assessed by the Global Assessment for AD (IGA) score of clear or almost clear as against the patients treated with placebo.

“We are encouraged that baricitinib met the primary endpoints in these two studies, and look forward to seeing the collective results of all five studies.”

Incidence of treatment-related adverse events and serious adverse events with baricitinib was similar to that of placebo.

Nasopharyngitis and headache were the most common treatment-related adverse events observed during the trials.

The trials did not report any venous thromboembolic events (VTEs), major adverse cardiovascular events (MACE), or deaths.

Eli Lilly and Company immunology development vice-president Lotus Mallbris said: “Atopic dermatitis is a chronic inflammatory skin disease that can negatively impact the quality of life for patients, and unfortunately there are limited treatment options, particularly oral medications.

“We are encouraged that baricitinib met the primary endpoints in these two studies, and look forward to seeing the collective results of all five studies.”

Baricitinib previously received approval for use in over 50 countries for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena